These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
198 related articles for article (PubMed ID: 8529760)
1. Comparison between acarbose, metformin, and insulin treatment in type 2 diabetic patients with secondary failure to sulfonylurea treatment. Calle-Pascual AL; Garcia-Honduvilla J; Martin-Alvarez PJ; Vara E; Calle JR; Munguira ME; Marañes JP Diabete Metab; 1995 Oct; 21(4):256-60. PubMed ID: 8529760 [TBL] [Abstract][Full Text] [Related]
2. Acarbose in ambulatory treatment of non-insulin-dependent diabetes mellitus associated to imminent sulfonylurea failure: a randomised-multicentric trial in primary health-care. Diabetes and Acarbose Research Group. Costa B; Piñol C Diabetes Res Clin Pract; 1997 Oct; 38(1):33-40. PubMed ID: 9347244 [TBL] [Abstract][Full Text] [Related]
3. A comparison of acarbose versus metformin as an adjuvant therapy in sulfonylurea-treated NIDDM patients. Bayraktar M; Van Thiel DH; Adalar N Diabetes Care; 1996 Mar; 19(3):252-4. PubMed ID: 8742572 [TBL] [Abstract][Full Text] [Related]
4. Acarbose in NIDDM patients with poor control on conventional oral agents. A 24-week placebo-controlled study. Lam KS; Tiu SC; Tsang MW; Ip TP; Tam SC Diabetes Care; 1998 Jul; 21(7):1154-8. PubMed ID: 9653611 [TBL] [Abstract][Full Text] [Related]
5. Effect of pioglitazone and acarbose on endothelial inflammation biomarkers during oral glucose tolerance test in diabetic patients treated with sulphonylureas and metformin. Derosa G; Mereu R; D'Angelo A; Salvadeo SA; Ferrari I; Fogari E; Gravina A; Palumbo I; Maffioli P; Randazzo S; Cicero AF J Clin Pharm Ther; 2010 Oct; 35(5):565-79. PubMed ID: 20831680 [TBL] [Abstract][Full Text] [Related]
6. Effects of alpha-glucosidase inhibitor (acarbose) combined with sulfonylurea or sulfonylurea and metformin in treatment of non-insulin-dependent diabetes mellitus. Vannasaeng S; Ploybutr S; Nitiyanant W; Peerapatdit T; Vichayanrat A J Med Assoc Thai; 1995 Nov; 78(11):578-85. PubMed ID: 8576667 [TBL] [Abstract][Full Text] [Related]
7. One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes. Hanefeld M; Brunetti P; Schernthaner GH; Matthews DR; Charbonnel BH; Diabetes Care; 2004 Jan; 27(1):141-7. PubMed ID: 14693980 [TBL] [Abstract][Full Text] [Related]
8. No relationship between carbohydrate intake and effect of acarbose on HbA1c or gastrointestinal symptoms in type 2 diabetic subjects consuming 30-60% of energy from carbohydrate. Wolever TM; Chiasson JL; Josse RG; Hunt JA; Palmason C; Rodger NW; Ross SA; Ryan EA; Tan MH Diabetes Care; 1998 Oct; 21(10):1612-8. PubMed ID: 9773719 [TBL] [Abstract][Full Text] [Related]
9. The use of Acarbose in Type 2 diabetic patients in secondary failure: effects on glycaemic control and diet induced thermogenesis. Brooks B; Molyneaux L; Zilkens R; Ross G; Yue DK Diabetes Res Clin Pract; 1998 Dec; 42(3):175-80. PubMed ID: 9925348 [TBL] [Abstract][Full Text] [Related]
10. Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison. Wang JS; Lin SD; Lee WJ; Su SL; Lee IT; Tu ST; Tseng YH; Lin SY; Sheu WH Clin Ther; 2011 Dec; 33(12):1932-42. PubMed ID: 22078152 [TBL] [Abstract][Full Text] [Related]
11. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial. Chiasson JL; Josse RG; Hunt JA; Palmason C; Rodger NW; Ross SA; Ryan EA; Tan MH; Wolever TM Ann Intern Med; 1994 Dec; 121(12):928-35. PubMed ID: 7734015 [TBL] [Abstract][Full Text] [Related]
12. Efficacy of 24-week monotherapy with acarbose, metformin, or placebo in dietary-treated NIDDM patients: the Essen-II Study. Hoffmann J; Spengler M Am J Med; 1997 Dec; 103(6):483-90. PubMed ID: 9428831 [TBL] [Abstract][Full Text] [Related]
13. Comparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and rosiglitazone or insulin and acarbose in type 2 diabetes. Yilmaz H; Gursoy A; Sahin M; Guvener Demirag N Acta Diabetol; 2007 Dec; 44(4):187-92. PubMed ID: 17726570 [TBL] [Abstract][Full Text] [Related]
14. Comparison of insulin with or without continuation of oral hypoglycemic agents in the treatment of secondary failure in NIDDM patients. Chow CC; Tsang LW; Sorensen JP; Cockram CS Diabetes Care; 1995 Mar; 18(3):307-14. PubMed ID: 7555472 [TBL] [Abstract][Full Text] [Related]
15. The effects of metformin on glycemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control. Robinson AC; Burke J; Robinson S; Johnston DG; Elkeles RS Diabetes Care; 1998 May; 21(5):701-5. PubMed ID: 9589227 [TBL] [Abstract][Full Text] [Related]
16. Metformin's effects on glucose and lipid metabolism in patients with secondary failure to sulfonylureas. Fanghänel G; Sánchez-Reyes L; Trujillo C; Sotres D; Espinosa-Campos J Diabetes Care; 1996 Nov; 19(11):1185-9. PubMed ID: 8908377 [TBL] [Abstract][Full Text] [Related]
17. The effect of a thiazolidinedione drug, troglitazone, on glycemia in patients with type 2 diabetes mellitus poorly controlled with sulfonylurea and metformin. A multicenter, randomized, double-blind, placebo-controlled trial. Yale JF; Valiquett TR; Ghazzi MN; Owens-Grillo JK; Whitcomb RW; Foyt HL Ann Intern Med; 2001 May; 134(9 Pt 1):737-45. PubMed ID: 11329231 [TBL] [Abstract][Full Text] [Related]